Avoro Capital Advisors LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Avoro Capital Advisors LLC reported 41 stock positions worth $7.5 billion. Its top holding was United Therapeutics (UTHR) at 12.1% of the portfolio, followed by Madrigal Pharmaceuticals (MDGL, 7.7%) and Ascendis Pharma A/S (ASND, 7.6%). Compared with Q1 2024, it opened 3 new positions, sold out of 8, added to 11 and reduced 9. The biggest buy was Avidity Biosciences (RNAM, shares +12%) and the biggest sale an exit from Viking Therapeutics (VKTX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001633313
- Portfolio Value
- $7.5B (Q2 2024)
- SEC Filing
- 0001104659-24-089335 ↗ filed Aug 14, 2024
Holdings Value
Holdings 41 stocks · $7.5B
| UTHR United Therapeutics Corp. | 12.13% | 2,858,888 | $910.7M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 7.67% | 2,055,555 | $575.9M | Add +5.7% |
| ASND Ascendis Pharma A/S | 7.62% | 4,196,661 | $572.3M | Add +5.8% |
| ARGX Argenx SE - ADR | 7.09% | 1,238,467 | $532.6M | No change |
| SRPT Sarepta Therapeutics Inc. | 6.31% | 3,000,000 | $474.0M | Reduce -30.9% |
| KRYS Krystal Biotech Inc. | 5.95% | 2,433,000 | $446.8M | Reduce -4.8% |
| APLS Apellis Pharmaceuticals Inc. | 5.68% | 11,111,111 | $426.2M | No change |
| BMRN Biomarin Pharmaceutical Inc. | 5.00% | 4,557,416 | $375.2M | Add +4.4% |
| CERE Cerevel Therapeutics Holding | 4.11% | 7,539,547 | $308.3M | Reduce -0.2% |
| XBI SS SPDR S&P Biotech ETF | 3.75% | 3,035,000 | $281.4M | Reduce -29.4% |
| FOLD Amicus Therapeutics Inc. | 3.62% | 27,400,000 | $271.8M | No change |
| RNAM Avidity Biosciences Inc. | 3.54% | 6,505,000 | $265.7M | Add +11.7% |
| ARWR Arrowhead Pharmaceuticals Inc. | 3.08% | 8,888,888 | $231.0M | Add +3.9% |
| XENE Xenon Pharmaceuticals Inc. | 2.94% | 5,666,666 | $220.9M | No change |
| ITCI Intra-Cellular Therapies Inc. | 2.74% | 3,000,000 | $205.5M | Add +21.2% |
| VERA Vera Therapeutics Inc. | 2.08% | 4,309,590 | $155.9M | Reduce -18.1% |
| MLTX Moonlake Immunotherapeutics | 1.62% | 2,770,000 | $121.8M | Add +7.4% |
| KYMR Kymera Therapeutics Inc. | 1.55% | 3,888,888 | $116.1M | No change |
| ALNY Alnylam Pharmaceuticals Inc. | 1.29% | 400,000 | $97.2M | Add +33.3% |
| IOVA Iovance Biotherapeutics Inc. | 1.25% | 11,700,000 | $93.8M | No change |
| SLNO Soleno Therapeutics Inc. | 1.14% | 2,091,666 | $85.3M | Add +28.7% |
| MRUS Merus NV | 1.07% | 1,355,000 | $80.2M | Add +52.4% |
| SNDX Syndax Pharmaceuticals Inc. | 1.06% | 3,888,437 | $79.8M | Reduce -7.9% |
| BCRX Biocryst Pharmaceuticals Inc. | 1.03% | 12,570,000 | $77.7M | Reduce -3.7% |
| KURA Kura Oncology Inc. | 0.97% | 3,541,505 | $72.9M | Reduce -8.0% |
| OCUL Ocular Therapeutix Inc. | 0.73% | 8,060,000 | $55.1M | Add +12.7% |
| MNKD Mannkind Corp. | 0.61% | 8,759,524 | $45.7M | Reduce -2.7% |
| PCVX Vaxcyte Inc. | 0.58% | 575,000 | $43.4M | No change |
| SYRE Spyre Therapeutics Inc. | 0.58% | 1,839,138 | $43.2M | No change |
| AUTL Autolus Therapeutics PLC | 0.57% | 12,345,678 | $43.0M | No change |
| TSHA Taysha Gene Therapies Inc. | 0.56% | 18,650,000 | $41.8M | No change |
| RARE Ultragenyx Pharmaceutical Inc. | 0.45% | 830,000 | $34.1M | No change |
| VRCA Verrica Pharmaceuticals Inc. | 0.39% | 3,999,999 | $29.2M | No change |
| TRML Tourmaline Bio Inc. | 0.38% | 2,222,222 | $28.6M | No change |
| CGON CG Oncology Inc. | 0.29% | 700,000 | $22.1M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 0.23% | 4,535,000 | $17.0M | No change |
| BCYC Bicycle Therapeutics PLC-ADR | 0.19% | 700,000 | $14.2M | New |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 0.06% | 2,849,402 | $4.2M | No change |
| DYN Dyne Therapeutics Inc. | 0.05% | 115,751 | $4.1M | New |
| ADVM Adverum Biotechnologies Inc. | 0.04% | 416,666 | $2.9M | No change |
| NGNE Neurogene Inc. | 0.01% | 22,029 | $802K | New |
Portfolio Sells Q1 2024 → Q2 2024
| VKTX Viking Therapeutics Inc. | Sold out | 0.00% | −3.43 |
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −2.67 |
| MGNX Macrogenics Inc. | Sold out | 0.00% | −1.06 |
| XBI SS SPDR S&P Biotech ETF | Reduce -29.4% | 3.75% | −1.01 |
| ROIV Roivant Sciences Ltd. | Sold out | 0.00% | −0.57 |
| VERA Vera Therapeutics Inc. | Reduce -18.1% | 2.08% | −0.57 |
| MRNS Marinus Pharmaceuticals Inc. | Sold out | 0.00% | −0.44 |
| RCKT Rocket Pharmaceuticals Inc. | Sold out | 0.00% | −0.40 |
| CRSP Crispr Therapeutics AG | Sold out | 0.00% | −0.33 |
| SRPT Sarepta Therapeutics Inc. | Reduce -30.9% | 6.31% | −0.25 |
| KYTX Kyverna Therapeutics Inc. | Sold out | 0.00% | −0.14 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -7.9% | 1.06% | −0.11 |
| KURA Kura Oncology Inc. | Reduce -8.0% | 0.97% | +0.01 |
| MNKD Mannkind Corp. | Reduce -2.7% | 0.61% | +0.13 |
| BCRX Biocryst Pharmaceuticals Inc. | Reduce -3.7% | 1.03% | +0.26 |
| CERE Cerevel Therapeutics Holding | Reduce -0.2% | 4.11% | +0.38 |
| KRYS Krystal Biotech Inc. | Reduce -4.8% | 5.95% | +0.65 |
Portfolio Buys Q1 2024 → Q2 2024
| RNAM Avidity Biosciences Inc. | Add +11.7% | 3.54% | +1.81 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +5.7% | 7.67% | +1.61 |
| ALNY Alnylam Pharmaceuticals Inc. | Add +33.3% | 1.29% | +0.77 |
| ITCI Intra-Cellular Therapies Inc. | Add +21.2% | 2.74% | +0.74 |
| ASND Ascendis Pharma A/S | Add +5.8% | 7.62% | +0.63 |
| MRUS Merus NV | Add +52.4% | 1.07% | +0.60 |
| BMRN Biomarin Pharmaceutical Inc. | Add +4.4% | 5.00% | +0.55 |
| SLNO Soleno Therapeutics Inc. | Add +28.7% | 1.14% | +0.33 |
| ARWR Arrowhead Pharmaceuticals Inc. | Add +3.9% | 3.08% | +0.22 |
| BCYC Bicycle Therapeutics PLC-ADR | New | 0.19% | +0.19 |
| MLTX Moonlake Immunotherapeutics | Add +7.4% | 1.62% | +0.11 |
| DYN Dyne Therapeutics Inc. | New | 0.05% | +0.05 |
| NGNE Neurogene Inc. | New | 0.01% | +0.01 |
| OCUL Ocular Therapeutix Inc. | Add +12.7% | 0.73% | −0.02 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $11.1B | UTHR, ASND, KRYS, MDGL, ARGX |
| Q1 2026 | 30 | $10.2B | UTHR, ASND, MDGL, KRYS, ARGX |
| Q4 2025Amended | 33 | $10.2B | UTHR, ASND, MDGL, ARGX, KRYS |
| Q3 2025 | 30 | $7.7B | ASND, UTHR, MDGL, ARGX, KRYS |
| Q2 2025 | 30 | $5.7B | ASND, UTHR, ARGX, MDGL, KRYS |
| Q1 2025 | 33 | $6.4B | UTHR, ASND, ARGX, MDGL, KRYS |
| Q4 2024 | 39 | $7.1B | UTHR, ARGX, ASND, MDGL, KRYS |
| Q3 2024 | 35 | $6.9B | UTHR, ASND, ARGX, KRYS, MDGL |
| Q2 2024 | 41 | $7.5B | UTHR, MDGL, ASND, ARGX, SRPT |
| Q1 2024 | 46 | $8.6B | UTHR, APLS, ASND, SRPT, MDGL |